Product
Ferric Citrate
Aliases
Auryxia, ferric citrate, KRX-0502
Name
Auryxia
INN Name
ferric citrate
FDA Approved
Yes
5 clinical trials
1 organization
13 indications
1 document
Indication
Anemia of Chronic Kidney DiseaseIndication
Chronic Kidney DiseaseIndication
AnaemiaIndication
Iron DeficiencyIndication
HyperphosphatemiaIndication
ChronicIndication
Renal AnemiaIndication
Disease ProgressionIndication
CardiovascularIndication
IronIndication
End-Stage Renal DiseaseIndication
Chronic InflammationClinical trial
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney DiseaseStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKDStatus: Completed, Estimated PCD: 2022-10-28
Clinical trial
Phosphate Binder Therapy and Chronic Kidney Disease in ChildrenStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Effect of Ferric Citrate on Time to a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality vs Placebo in Adults With Advanced CKDStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on HemodialysisStatus: Terminated, Estimated PCD: 2017-09-29
Document
DailyMed Label: AuryxiaOrganization
Akebia Therapeutics, Inc.